Clinical trials: Chordomas, open to volunteers
Melanoma, Li-Fraumeni Syndrome
Clinical Genetics Branch Eligibility Screening Survey
Background: Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer in order to improve our understanding of cancer and to improve cancer care.
- Conditions
- Melanoma, Li-Fraumeni Syndrome, Pulmonary Blastoma, Chordoma
- Trial name
- NCT07005297
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Chordoma of Spine, Chordoma of Skull Base
Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma
In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic…
- Conditions
- Chordoma of Spine, Chordoma of Skull Base, Chordoma of Sacrum
- Trial name
- Canon (NCT06463262)
- Testing
- ctDNA
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chordoma
Children and Adults With Chordoma
Background: Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways.
- Trial name
- NCT03910465
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected…
- Trial name
- ETOILE (NCT02838602)
- Testing
- Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
- Where
- 21 sites in France
- Volunteers
- 250 people
- Sponsor
- Hospices Civils de Lyon
Chordoma, Chondrosarcoma
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
The project is planned as a phase II clinical trial with a low level of intervention, for the prospective evaluation of the clinical results of radical or adjuvant treatment by proton therapy in chordomas and chondrosarcomas of…
- Trial name
- NCT05861245
- Testing
- 5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Quironsalud
Chordoma, Chondrosarcoma
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to…
- Conditions
- Chordoma, Chondrosarcoma, Ewing Sarcoma, Osteosarcoma
- Trial name
- P1V2 (NCT06029218)
- Testing
- Proteus ONE one daily beam, Proteus ONE two daily beam
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Centre Antoine Lacassagne
Sarcoma
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
- Trial name
- TNT (NCT03886311)
- Testing
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Bone Sarcoma, Chondrosarcoma
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects.
- Conditions
- Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone
- Trial name
- NCT05033288
- Testing
- Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Chordomas, Chordoma
Pembrolizumab and Pemetrexed for Progressive Chordoma
Primary Objective: 1. To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression.
- Trial name
- NCT06794645
- Testing
- Pembrolizumab, Pemetrexed Phase 2
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Saint John's Cancer Institute
Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
- Trial name
- SACRO (NCT02986516)
- Testing
- Randomized Cohort, Prospective cohort
- Where
- 28 sites in Austria, Germany and 8 more
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Bone Neoplasm of Vertebral Column, Chordoma
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Rationale: Chordomas and chondrosarcomas located in the axial skeleton are malignant neoplasms of bone. These tumors share the same clinical challenges, as the effect of the disease is more a function of their local…
- Conditions
- Bone Neoplasm of Vertebral Column, Chordoma, Chondrosarcoma, Magnetic Resonance Imaging
- Trial name
- CHIPT (NCT04832620)
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center